Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease

NCT06399107 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease
Sickle-Cell Disease With Crisis

Interventions

GENETIC: Drug Product is administered by IV infusion following myeloablative conditioning with busulfan

Sponsor

Essen Biotech